Trial Profile

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin degludec/liraglutide (Primary) ; Insulin aspart; Insulin glargine
Indications Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms DUAL VII
Sponsors Novo Nordisk

08 Nov 2019 Results of post hoc analysis of two trials (DUAL V and DUAL VII) were published in the Diabetic Medicinepublished in the Diabetic Medicine
23 Jan 2019 According to a Novo Nordisk media release, Xultophy was approved by Health Canada in April 2018 based on data from the DUAL clinical development program.
05 Oct 2018 Results of post hoc analysis evaluating the treatment complexity of IDegLira vs. BB in terms of number of injections and dose adjustments presented at the 54th Annual Meeting of the European Association for the Study of Diabetes

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com